The role of progesterone signaling in the pathogenesis of uterine leiomyoma

Molecular and Cellular Endocrinology

Volumn 358, Issue 2, 2012, Pages 223-231

  Kim, J Julie ^a   Sefton, Elizabeth C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Division of Reproductive Biology Research   (United States)

Author keywords

Leiomyoma; Progesterone; Progesterone receptor; Uterine leiomyoma

Indexed keywords

2 METHOXYESTRADIOL; AROMATASE; ASOPRISNIL; CATECHOL METHYLTRANSFERASE; CYCLINE; ESTRADIOL; ESTROGEN; GONADORELIN AGONIST; GROWTH FACTOR; J 687; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MICRORNA 20A; MICRORNA 21; MICRORNA 26A; MIFEPRISTONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; PROTEIN TYROSINE KINASE; TELAPRISTONE ACETATE; TRANSCRIPTION FACTOR FKHR; ULIPRISTAL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ALCOHOL CONSUMPTION; APOPTOSIS; BONE DENSITY; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; DISEASE ASSOCIATION; GENE; GENE CONTROL; HORMONAL REGULATION; HUMAN; HYPERTENSION; HYSTERECTOMY; KRUPPEL LIKE TRANSCRIPTION FACTOR 11 GENE; MYOMECTOMY; NONHUMAN; OBESITY; ORAL CONTRACEPTION; PARITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RACE; RED MEAT; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; ULTRASOUND SURGERY; UTERUS BLEEDING; UTERUS MYOMA;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEIOMYOMA; PROGESTERONE; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 84861528492     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.044     Document Type: Review

References (146)

1. Aharoni A., Reiter A., Golan D., Paltiely Y., Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br. J. Obstet. Gynecol. 1988, 95:510-513.
2. Al Hilli M.M., Stewart E.A. Magnetic resonance-guided focused ultrasound surgery. Semin. Reprod. Med. 2010, 28:242-249.
3. Arici A., Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am. J. Obstet. Gynecol. 2003, 188:76-83.
4. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 2008, 29:217-233.
5. Bagaria M., Suneja A., Vaid N.B., Guleria K., Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust. N Z J Obstet. Gynecol. 2009, 49:77-83.
6. Baird D.T., Brown A., Critchley H.O., Williams A.R., Lin S., Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 2003, 18:61-68.
7. Ballare C., Vallejo G., Vicent G.P., Saragueta P., Beato M. Progesterone signaling in breast and endometrium. J. Steroid Biochem. Mol. Biol. 2006, 102:2-10.
8. Barbarisi A., Petillo O., Di Lieto A., Melone M.A., Margarucci S., Cannas M., Peluso G. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J. Cell. Physiol. 2001, 186:414-424.
9. Bifulco G., Miele C., Pellicano M., Trencia A., Ferraioli M., Paturzo F., Tommaselli G.A., Beguinot F., Nappi C. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol. Hum. Reprod. 2004, 10:43-48.
10. Boehm K.D., Daimon M., Gorodeski I.G., Sheean L.A., Utian W.H., Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol. Reprod. Dev. 1990, 27:93-101.
11. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell. 2001, 8:269-280.
12. Burroughs K.D., Fuchs-Young R., Davis B., Walker C.L. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol. Reprod. 2000, 63:1322-1330.
13. Cameron S.T., Critchley H.O., Thong K.J., Buckley C.H., Williams A.R., Baird D.T. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod. 1996, 11:2518-2526.
14. Carnevale R.P., Proietti C.J., Salatino M., Urtreger A., Peluffo G., Edwards D.P., Boonyaratanakornkit V., Charreau E.H., Bal de Kier Joffe E., Schillaci R., Elizalde P.V. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol. Endocrinol. 2007, 21:1335-1358.
15. Carr B.R., Marshburn P.B., Weatherall P.T., Bradshaw K.D., Breslau N.A., Byrd W., Roark M., Steinkampf M.P. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J. Clin. Endocrinol. Metab. 1993, 76:1217-1223.
16. Cermik D., Arici A., Taylor H.S. Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma. Fertil Steril 2002, 78:979-984.
17. Chegini N., Tang X.M., Ma C. Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J. Clin. Endocrinol. Metab. 1999, 84:4138-4143.
18. Chegini, N., 2010. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin. Reprod. Med. 28, 180-203.
19. Chen W., Ohara N., Wang J., Xu Q., Liu J., Morikawa A., Sasaki H., Yoshida S., Demanno D.A., Chwalisz K., Maruo T. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab. 2006, 91:1296-1304.
20. Chiaffarino F., Parazzini F., La Vecchia C., Chatenoud L., Di Cintio E., Marsico S. Diet and uterine myomas. Obstet. Gynecol. 1999, 94:395-398.
21. Chwalisz, K., Larsen, L., Mattia-Goldberg, C., Edmonds, A., Elger, W., Winkel, C.A., 2007. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril.
22. Ciarmela P., Bloise E., Gray P.C., Carrarelli P., Islam M.S., De Pascalis F., Severi F.M., Vale W., Castellucci M., Petraglia F. Activin-a and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid. J. Clin. Endocrinol. Metab. 2011, 96:755-765.
23. Cook J.D., Davis B.J., Goewey J.A., Berry T.D., Walker C.L. Identification of a sensitive period for developmental programming that increases risk for uterine leiomyoma in Eker rats. Reprod. Sci. 2007, 14:121-136.
24. Cramer S.F., Patel A. The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 1990, 94:435-438.
25. De Falco M., Staibano S., D'Armiento F.P., Mascolo M., Salvatore G., Busiello A., Carbone I.F., Pollio F., Di Lieto A. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J. Soc. Gynecol. Investig. 2006, 13:297-303.
26. Di X., Yu L., Moore A.B., Castro L., Zheng X., Hermon T., Dixon D. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum. Reprod. 2008, 23:1873-1883.
27. Dou Q., Zhao Y., Tarnuzzer R.W., Rong H., Williams R.S., Schultz G.S., Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J. Clin. Endocrinol. Metab. 1996, 81:3222-3230.
28. Edwards R.D., Moss J.G., Lumsden M.A., Wu O., Murray L.S., Twaddle S., Murray G.D. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N. Engl. J. Med. 2007, 356:360-370.
29. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 2003, 101:243-250.
30. Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S., Guzick D.S. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive Gynecol. 2005, 12:227-233.
31. Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009, 24:1870-1879.
32. Feng C., Meldrum S., Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int. J. Gynecol. Obstet. 2010, 109:121-124.
33. Fiscella K., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet. Gynecol. 2006, 108:1381-1387.
34. Flynn M., Jamison M., Datta S., Myers E. Health care resource use for uterine fibroid tumors in the United States. Am. J. Obstet. Gynecol. 2006, 195:955-964.
35. Fong Y.F., Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 1999, 60:51-53.
36. Freed M.M., Spies J.B. Uterine artery embolization for fibroids: a review of current outcomes. Semin. Reprod. Med. 2010, 28:235-241.
37. Friedman A.J., Daly M., Juneau-Norcross M., Rein M.S., Fine C., Gleason R., Leboff M. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J. Clin. Endocrinol. Metab. 1993, 76:1439-1445.
38. Friedman A.J., Daly M., Juneau-Norcross M., Gleason R., Rein M.S., LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum. Reprod. 1994, 9:1618-1625.
39. Gao Z., Matsuo H., Wang Y., Nakago S., Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 2001, 86:5593-5599.
40. Giudice L.C., Irwin J.C., Dsupin B.A., Pannier E.M., Jin I.H., Vu T.H., Hoffman A.R. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum. Reprod. 1993, 8:1796-1806.
41. Grigorieva V., Chen-Mok M., Tarasova M., Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003, 79:1194-1198.
42. Hammoud A.O., Asaad R., Berman J., Treadwell M.C., Blackwell S., Diamond M.P. Volume change of uterine myomas during pregnancy: do myomas really grow?. J. Minim. Invasive Gynecol. 2006, 13:386-390.
43. Harrison-Woolrych M.L., Charnock-Jones D.S., Smith S.K. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J. Clin. Endocrinol. Metab. 1994, 78:1179-1184.
44. Hassan M.H., Salama S.A., Arafa H.M., Hamada F.M., Al-Hendy A. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J. Clin. Endocrinol. Metab. 2007, 92:3949-3957.
45. Hassan M.H., Salama S.A., Zhang D., Arafa H.M., Hamada F.M., Fouad H., Walker C.C., Al-Hendy A. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil. Steril. 2010, 93:239-250.
46. Hermon T.L., Moore A.B., Yu L., Kissling G.E., Castora F.J., Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008, 453:557-569.
47. Hilario S.G., Bozzini N., Borsari R., Baracat E.C. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil. Steril. 2009, 91:240-243.
48. Hodges L.C., Houston K.D., Hunter D.S., Fuchs-Young R., Zhang Z., Wineker R.C., Walker C.L. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Mol. Cell. Endocrinol. 2002, 196:11-20.
49. Hoekstra, A.V., Sefton, E.C., Berry, E., Lu, Z., Hardt, J., Marsh, E., Yin, P., Clardy, J., Chakravarti, D., Bulun, S., Kim, J.J., 2009. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J. Clin. Endocrinol. Metab. submitted for publication.
50. Horne F.M., Blithe D.L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update 2007, 13:567-580.
51. Howe S.R., Gottardis M.M., Everitt J.I., Goldsworthy T.L., Wolf D.C., Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol. 1995, 146:1568-1579.
52. Hwu Y.M., Li S.H., Lee R.K., Tsai Y.H., Yeh T.S., Lin S.Y. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil. Steril. 2008, 89:468-471.
53. Imir A.G., Lin Z., Yin P., Deb S., Yilmaz B., Cetin M., Cetin A., Bulun S.E. Aromatase expression in uterine leiomyomata is regulated primarily by proximal promoters I.3/II. J. Clin. Endocrinol. Metab. 2007, 92:1979-1982.
54. Ishikawa H., Reierstad S., Demura M., Rademaker A.W., Kasai T., Inoue M., Usui H., Shozu M., Bulun S.E. High aromatase expression in uterine leiomyoma tissues of African-American women. J. Clin. Endocrinol. Metab. 2009, 94:1752-1756.
55. Ishikawa H., Ishi K., Serna V.A., Kakazu R., Bulun S.E., Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010, 151:2433-2442.
56. Jarvela I., Tekay A., Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum. Reprod. 1998, 13:3379-3383.
57. Karra L., Shushan A., Ben-Meir A., Rojansky N., Klein B.Y., Shveiky D., Levitzki R., Ben-Bassat H. Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil. Steril. 2010, 93:2646-2651.
58. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynaecol. 1989, 160:637-641.
59. Kawaguchi K., Fujii S., Konishi I., Iwai T., Nanbu Y., Nonogaki H., Ishikawa Y., Mori T. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch. A Pathol. Anat. Histopathol. 1991, 419:309-315.
60. Kayisli U.A., Berkkanoglu M., Kizilay G., Senturk L., Arici A. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. Reprod. Sci. 2007, 14:678-686.
61. Kjerulff K.H., Langenberg P., Seidman J.D., Stolley P.D., Guzinski G.M. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J. Reprod. Med. 1996, 41:483-490.
62. Klemke, M., Meyer, A., Hashemi Nezhad, M., Belge, G., Bartnitzke, S., Bullerdiek, J., 2010. Loss of let-7 binding sites resulting from truncations of the 3' untranslated region of HMGA2 mRNA in uterine leiomyomas. Cancer Genet Cytogenet 196, 119-23.
63. Kobayashi T., Hirayama Y., Kobayashi E., Kubo Y., Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. 1995, 9:70-74.
64. Kovacs K.A., Lengyel F., Kornyei J.L., Vertes Z., Szabo I., Sumegi B., Vertes M. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J. Steroid Biochem. Mol. Biol. 2003, 87:233-240.
65. Kovacs K.A., Lengyel F., Vertes Z., Kornyei J.L., Gocze P.M., Sumegi B., Szabo I., Vertes M. Phosphorylation of PTEN (phosphatase and tensin homologue deleted on chromosome ten) protein is enhanced in human fibromyomatous uteri. J. Steroid Biochem. Mol. Biol. 2007, 103:196-199.
66. Kovacs K.A., Lengyel F., Wilhelm F., Vertes Z., Sumegi B., Vertes M. Involvement of FKHR (FOXO1) transcription factor in human uterus leiomyoma growth. Fertil. Steril. 2010, 94:1491-1495.
67. Kubo Y., Kikuchi Y., Mitani H., Kobayashi E., Kobayashi T., Hino O. Allelic loss at the tuberous sclerosis (Tsc2) gene locus in spontaneous uterine leiomyosarcomas and pituitary adenomas in the Eker rat model. Jpn. J. Cancer Res. 1995, 86:828-832.
68. Lamminen S., Rantala I., Helin H., Rorarius M., Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol. Obstet. Invest. 1992, 34:111-114.
69. Lange C.A. Integration of progesterone receptor action with rapid signaling events in breast cancer models. J. Steroid Biochem. Mol. Biol. 2008, 108:203-212.
70. Lee B.S., Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J. Clin. Endocrinol. Metab. 2001, 86:913-920.
71. Lengyel F., Vertes Z., Kovacs K.A., Kornyei J.L., Sumegi B., Vertes M. Effect of estrogen and inhibition of phosphatidylinositol-3 kinase on Akt and FOXO1 in rat uterus. Steroids 2007, 72:422-428.
72. Levens E.D., Potlog-Nahari C., Armstrong A.Y., Wesley R., Premkumar A., Blithe D.L., Blocker W., Nieman L.K. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 2008, 111:1129-1136.
73. Liang M., Wang H., Zhang Y., Lu S., Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol. Ther. 2006, 5:28-33.
74. Luo X., Chegini N. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin. Reprod. Med. 2008, 26:500-514.
75. Luo X., Yin P., Reierstad S., Ishikawa H., Lin Z., Pavone M.E., Zhao H., Marsh E.E., Bulun S.E. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 2009, 94:4533-4539.
76. Luo, X., Yin, P., Coon, V.J., Cheng, Y.H., Wiehle, R.D., Bulun, S.E., 2010. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil. Steril. 93, 2668-73.
77. Malone L.J. Myomectomy: recurrence after removal of solitary and multiple myomas. Obstet. Gynecol. 1969, 34:200-203.
78. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
79. Mangrulkar R.S., Ono M., Ishikawa M., Takashima S., Klagsbrun M., Nowak R.A. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol. Reprod. 1995, 53:636-646.
80. Marelli G., Codegoni A.M., Bizzi A. Estrogen and progesterone receptors in leiomyomas and normal uterine tissues during reproductive life. Acta Eur. Fertil. 1989, 20:19-22.
81. Marsh E.E., Lin Z., Yin P., Milad M., Chakravarti D., Bulun S.E. Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil. Steril. 2008, 89:1771-1776.
82. Maruo T., Matsuo H., Samoto T., Shimomura Y., Kurachi O., Gao Z., Wang Y., Spitz I.M., Johansson E. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000, 65:585-592.
83. Maruo T., Ohara N., Matsuo H., Xu Q., Chen W., Sitruk-Ware R., Johansson E.D. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007, 75:S99-S103.
84. Matsuo H., Maruo T., Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J. Clin. Endocrinol. Metab. 1997, 82:293-299.
85. Mixson W.T., Hammond D.O. Response of fibromyomas to a progestin. Am. J. Obstet. Gynecol. 1961, 82:754-760.
86. Morikawa A., Ohara N., Xu Q., Nakabayashi K., DeManno D.A., Chwalisz K., Yoshida S., Maruo T. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum. Reprod. 2008, 23:944-951.
87. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab. 1993, 76:513-517.
88. Murphy A.A., Morales A.J., Kettel L.M., Yen S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995, 64:187-190.
89. Mutter G.L., Bergeron C., Deligdisch L., Ferenczy A., Glant M., Merino M., Williams A.R., Blithe D.L. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. 2008, 21:591-598.
90. Nagata C., Nakamura K., Oba S., Hayashi M., Takeda N., Yasuda K. Association of intakes of fat, dietary fibre, soya isoflavones and alcohol with uterine fibroids in Japanese women. Br. J. Nutr. 2009, 101:1427-1431.
91. Narvekar N., Cameron S., Critchley H.O., Lin S., Cheng L., Baird D.T. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J. Clin. Endocrinol. Metab. 2004, 89:2491-2497.
92. Neiger R., Sonek J.D., Croom C.S., Ventolini G. Pregnancy-related changes in the size of uterine leiomyomas. J. Reprod. Med. 2006, 51:671-674.
93. Nierth-Simpson E.N., Martin M.M., Chiang T.C., Melnik L.I., Rhodes L.V., Muir S.E., Burow M.E., McLachlan J.A. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology 2009, 150:2436-2445.
94. Norian J.M., Malik M., Parker C.Y., Joseph D., Leppert P.C., Segars J.H., Catherino W.H. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod. Sci. 2009, 16:1153-1164.
95. Ohara N., Morikawa A., Chen W., Wang J., DeManno D.A., Chwalisz K., Maruo T. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod. Sci. 2007, 14:20-27.
96. Orbo A., Arnes M., Pettersen I., Larsen K., Hanssen K., Moe B. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet. Gynecol. Scand. 2010, 89:1438-1446.
97. Pan Q., Luo X., Chegini N. Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J. Cell. Mol. Med. 2008, 12:227-240.
98. Pan, Q., Luo, X., Chegini, N., 2010. microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Mol Hum Reprod 16, 215-27.
99. Parsanezhad M.E., Azmoon M., Alborzi S., Rajaeefard A., Zarei A., Kazerooni T., Frank V., Schmidt E.H. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil. Steril. 2009, 93:192-198.
100. Peddada S.D., Laughlin S.K., Miner K., Guyon J.P., Haneke K., Vahdat H.L., Semelka R.C., Kowalik A., Armao D., Davis B., Baird D.D. Growth of uterine leiomyomata among premenopausal black and white women. Proc. Nat. Acad. Sci. USA 2008, 105:19887-19892.
101. Peng L., Wen Y., Han Y., Wei A., Shi G., Mizuguchi M., Lee P., Hernando E., Mittal K., Wei J.J. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil. Steril. 2009, 91:2664-2675.
102. Reinsch R.C., Murphy A.A., Morales A.J., Yen S.S. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am. J. Obstet. Gynecol. 1994, 170:1623-1627. Discussion 1627-8.
103. Robinson-Rechavi M., Escriva Garcia H., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 2003, 116:585-586.
104. Rosati P., Exacoustos C., Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J. Ultrasound Med. 1992, 11:511-515.
105. Ross R.K., Pike M.C., Vessey M.P., Bull D., Yeates D., Casagrande J.T. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br. Med. J. (Clin Res Ed) 1986, 293:359-362.
106. Sadan O., van Iddekinge B., van Gelderen C.J., Savage N., Becker P.J., van der Walt L.A., Robinson M. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann. Clin. Biochem. 1987, 24(Pt 3):263-267.
107. Salama S.A., Kamel M.W., Botting S., Salih S.M., Borahay M.A., Hamed A.A., Kilic G.S., Saeed M., Williams M.Y., Diaz-Arrastia C.R. Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS One 2009, 4:e7356.
108. Sasaki H., Ohara N., Xu Q., Wang J., DeManno D.A., Chwalisz K., Yoshida S., Maruo T. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab. 2007, 92:616-623.
109. Sayed G.H., Zakherah M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynaecol. Obstet. 2011, 112:126-130.
110. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
111. Shimomura Y., Matsuo H., Samoto T., Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J. Clin. Endocrinol. Metab. 1998, 83:2192-2198.
112. Shozu M., Murakami K., Inoue M. Aromatase and leiomyoma of the uterus. Semin. Reprod. Med. 2004, 22:51-60.
113. Shushan A., Rojansky N., Laufer N., Klein B.Y., Shlomai Z., Levitzki R., Hartzstark Z., Ben-Bassat H. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum. Reprod. 2004, 19:1957-1967.
114. Soysal S., Soysal M.E. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol. Obstet. Invest. 2005, 59:29-35.
115. Spitz I.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr. Opin. Obstet. Gynecol. 2009, 21:318-324.
116. Starczewski A., Iwanicki M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol. Pol. 2000, 71:1221-1225.
117. Stratton P., Levens E.D., Hartog B., Piquion J., Wei Q., Merino M., Nieman L.K. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010, 93:2035-2041.
118. Strawn E.Y., Novy M.J., Burry K.A., Bethea C.L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am. J. Obstet. Gynecol. 1995, 172:1837-1843. Discussion 1843-4.
119. Suo G., Jiang Y., Cowan B., Wang J.Y. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol. Reprod. 2009, 81:749-758.
120. Tang X.M., Dou Q., Zhao Y., McLean F., Davis J., Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol. Hum. Reprod. 1997, 3:233-240.
121. Tasci Y., Caglar G.S., Kayikcioglu F., Cengiz H., Yagci B., Gunes M. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus. Arch. Gynecol. Obstet. 2009, 280:39-42.
122. Tsuiji K., Takeda T., Li B., Kondo A., Ito M., Yaegashi N. Establishment of a novel xenograft model for human uterine leiomyoma in immunodeficient mice. Tohoku J. Exp. Med. 2010, 222:55-61.
123. Vallejo G., Ballare C., Baranao J.L., Beato M., Saragueta P. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells. Mol. Endocrinol. 2005, 19:3023-3037.
124. van der Ven L.T., Gloudemans T., Roholl P.J., van Buul-Offers S.C., Bladergroen B.A., Welters M.J., Sussenbach J.S., den Otter W. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I. Int. J. Cancer 1994, 59:427-434.
125. Vollenhoven B.J., Herington A.C., Healy D.L. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J. Clin. Endocrinol. Metab. 1993, 76:1106-1110.
126. Wang J., Ohara N., Wang Z., Chen W., Morikawa A., Sasaki H., DeManno D.A., Chwalisz K., Maruo T. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum. Reprod. 2006, 21:1869-1877.
127. Wei J.J., Soteropoulos P. MicroRNA: a new tool for biomedical risk assessment and target identification in human uterine leiomyomas. Semin. Reprod. Med. 2008, 26:515-521.
128. Wildemeersch D., Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002, 102:74-79.
129. Wilkens J., Chwalisz K., Han C., Walker J., Cameron I.T., Ingamells S., Lawrence A.C., Lumsden M.A., Hapangama D., Williams A.R., Critchley H.O. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J. Clin. Endocrinol. Metab. 2008, 93:4664-4671.
130. Wilkens J., Williams A.R., Chwalisz K., Han C., Cameron I.T., Critchley H.O. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Hum. Reprod. 2009, 24:1036-1044.
131. Williams, A.R., Critchley, H.O., Osei, J., Ingamells, S., Cameron, I.T., Han, C., Chwalisz, K., 2007. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod.
132. Worda C., Sator M.O., Schneeberger C., Jantschev T., Ferlitsch K., Huber J.C. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum. Reprod. 2003, 18:262-266.
133. Xu Q., Takekida S., Ohara N., Chen W., Sitruk-Ware R., Johansson E.D., Maruo T. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 2005, 90:953-961.
134. Xu Q., Ohara N., Chen W., Liu J., Sasaki H., Morikawa A., Sitruk-Ware R., Johansson E.D., Maruo T. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum. Reprod. 2006, 21:2408-2416.
135. Xu Q., Ohara N., Liu J., Nakabayashi K., DeManno D., Chwalisz K., Yoshida S., Maruo T. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1002-E1011.
136. Xu Q., Ohara N., Liu J., Amano M., Sitruk-Ware R., Yoshida S., Maruo T. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol. Hum. Reprod. 2008, 14:181-191.
137. Xu Q., Qiu L., Zhu L., Luo L., Xu C. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Contraception 2010, 82:301-308.
138. Yamada T., Nakago S., Kurachi O., Wang J., Takekida S., Matsuo H., Maruo T. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum. Reprod. 2004, 19:815-821.
139. Yin P., Lin Z., Cheng Y.H., Marsh E.E., Utsunomiya H., Ishikawa H., Xue Q., Reierstad S., Innes J., Thung S., Kim J.J., Xu E., Bulun S.E. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 2007, 92:4459-4466.
140. Yin X.J., Wang G., Khan-Dawood F.S. Requirements of phosphatidylinositol-3 kinase and mammalian target of rapamycin for estrogen-induced proliferation in uterine leiomyoma- and myometrium-derived cell lines. Am. J. Obstet. Gynecol. 2007, 196:176 e1-5.
141. Yin, P., Lin, Z., Reierstad, S., Wu, J., Ishikawa, H., Marsh, E.E., Innes, J., Cheng, Y., Pearson, K., Coon, J.S.t., Kim, J.J., Chakravarti, D., Bulun, S.E., 2010. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer. Res. 70, 1722-30.
142. Ying Z., Weiyuan Z. Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. Gynecol. Endocrinol. 2009, 25:520-523.
143. Yu L., Saile K., Swartz C.D., He H., Zheng X., Kissling G.E., Di X., Lucas S., Robboy S.J., Dixon D. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol. Med. 2008, 14:264-275.
144. Yu, L., Moore, A.B., Dixon, D., 2010. Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma. Semin. Reprod. Med. 28, 180-203.
145. Zavadil, J., Ye, H., Liu, Z., Wu, J., Lee, P., Hernando, E., Soteropoulos, P., Toruner, G.A., Wei, J.J., 2010. Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One 5, e12362.
146. Zhu M.L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 2008, 15:841-849.